|
Dr. Mircea is Chief of the Medical Oncology
Department, Institute
of Oncology Bucharest.
His main field of research activity in oncology is in lung cancer. He was a
pioneer promoting adjuvant chemotherapy for non-small-cell lung cancer in Romania.
His experience addressing this issue was published in the 'Lung Cancer' journal.
Other important studies are; evaluating
high dose cisplatin as neoadjuvant chemotherapy, preoperative chemotherapy and
concurrent chemo-radiation in locally advanced non-small-cell lung cancer (NSCLC).
These studies have been presented at the European Society for Medical Oncology
(ESMO), American Society of Clinical Oncology (ASCO) and International
Association for the Study of Lung Cancer (IASLC) meetings. Some of those
studies (and relevant personal points of view) on various controversial issues
have been published in peer-reviewed international journals, (Lung Cancer,
Journal of Clinical Oncology, and Journal of B.U.ON).
His editorial activity includes two
guidelines (lung and breast cancer), and contribution to textbooks addressing
lung, breast and gastric cancer topics.
He is a member of the Board of Directors of
the Balkan Union of Oncology. Part of
his research activity included participation as principal investigator in many of
the phase II and III international clinical trials, focusing on targeted
therapy in breast and lung cancer. In turn, this promised new drugs for
pancreatic and lung cancer, as well as new antiemetic regimens. His most
relevant contribution in this area was the use of erlotinib and other
innovative second line chemotherapy regimens in non-small-cell lung cancer,
which since have been published as full text papers in The New England Journal
of Medicine and Journal of Clinical Oncology.
| 
